NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. (“Emergent Biosolutions” or the “Company”) (NYSE: EBS) between January 11, 2016 and June 21, 2016.
You are hereby notified that a class action has been commenced in the USDC for the District of Maryland. If you purchased or otherwise acquired Emergent Biosolutions securities between January 11, 2016 and June 21, 2016, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that defendants issued materially false and misleading information regarding the Company’s business and financial prospects, particularly in relation to potential contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. The complaint further alleges that these positive statements caused the stock to trade at artificially inflated prices, allowing insiders to sell their shares at these inflated prices.
On June 22, 2016, before the open of trading, Emergent Biosolutions announced that the U.S. government had notified the Company it would only be purchasing 29.4 million doses of the vaccine over the following five years—an amount approximately one third less than the original contract. In addition, the Company disclosed that the government was seeking other anthrax vaccines, and that it was putting its supply bid out to other companies.
If you suffered a loss in Emergent Biosolutions you have until September 19, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.